Back HIV/AIDS HIV/AIDS Topics HIV Prevention

U.K.'s Largest Sexual Health Clinic Saw 40% Drop in New HIV Diagnoses in 2016

The clinic at 56 Dean Street in Soho, central London, the largest sexual health clinic in the U.K., saw an unprecedented 40% drop in new HIV diagnoses this year. Another clinic, the Mortimer Market Centre a mile away from Dean Street, has seen an even bigger 50% fall.

alt

Read more:

First Large Study of Long-Acting Injectable for HIV Prevention Now Underway

The National Institutes of Health and industry collaborators last week launched a large-scale clinical trial to test long-acting injectable cabotegravir for HIV prevention. Study HPTN 083 will compare cabotegravir injections administered every 8 weeks versus once-daily oral tenofovir/emtricitabine (Truvada) pre-exposure prophylaxis (PrEP). Results are expected in 2021.

alt

Read more:

4. PrEP Use Widens, But Disparities Remain

Pre-exposure prophylaxis (PrEP) was again a major HIV story in 2016. The latest figures from a pharmacy survey by Gilead Sciences showed that more than 79,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for HIV prevention, but the survey does not include all PrEP providers and most experts think this estimate is low.

alt

Read more:

1. HIV Undetectable = Uninfectious

Evidence continues to accumulate showing that HIV-positive people on effective combination antiretroviral therapy (ART) with a consistently undetectable viral load have a very low -- perhaps as low as zero -- risk of transmitting the virus.

alt

Read more:

5. HIV Prevention for Women

Use of Truvada for pre-exposure prophylaxis (PrEP) is highly effective and is now widely used among gay men, but biomedical HIV prevention for women has lagged behind.

alt

Read more: